towards linking the development and delivery of care for
TRANSCRIPT
![Page 1: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/1.jpg)
04/11/23
Towards Linking the Development and Delivery of Care for Cardiovascular Diseases:Designing Medical Device Supply Chain for the Unserved & Underserved Global Economies
Kingshuk K. SinhaUniversity of Minnesota
Joint work with Emily McIlvaine, Ph.D. Student
Cincinnati Innovations in Healthcare Delivery 2006September 22, 2006
![Page 2: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/2.jpg)
04/11/23
“What We Did Not See First, our call for papers did not elicit any studies focused on the biotech, pharmaceutical, or medical industry sectors. While research in these sectors has been published in related journals ….. we found no publications in recent issues of Production and Operations Management and very few overall directly related to production and operations management. Given the growth and significance of the biotech, pharmaceutical, and medical industry sectors around the globe, it is imperative we begin to identify and address the unique production and operations management challenges faced by these industry sectors.” (p. 121)
![Page 3: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/3.jpg)
04/11/23
“Industry studies is an observational science…..the systems we study involve companies and markets and institutions and their interactions ….. we must observe if we are to accurately understand and describe the remarkable complexity of it all.”
Reflections on Industry Studies
“We know that we need a microscope to see very small things …… Seeing large things, like industries, would be much simpler if we had a macroscope… Unfortunately we don't have a real macroscope.”
“Statistics is in fact our attempt at a macroscope but it is one that only functions erratically. It functions erratically because if we have the right overall picture, then the statistics can size it right for us, and tell us more about it, but if we don't have it right, the statistics won't tell us that we don't have it right and we can be very wrong.”
(Source: “Industry Studies: An Observational Science,” Speech by Dr. Ralph Gomory at the Annual Sloan Industry Center Meeting, Boston December 5, 2005.)
![Page 4: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/4.jpg)
04/11/23
An Introduction to the Research Program:The Central Question
How can the development of care be linked with the delivery of care, globally and effectively?
“Effectively” = Right care at the right place at the right time at the right price
![Page 5: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/5.jpg)
04/11/23
Outline
Health Care Supply Chain
Medical Device Supply Chain
Cardiovascular Disease-Centric Medical Device Supply Chain
Some Considerations
![Page 6: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/6.jpg)
04/11/23
Health Care Supply Chain
![Page 7: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/7.jpg)
04/11/23
Pharma
Biotech
Dev
elop
men
t of c
are
Health Care Supply Chain from End-to-End: Linking the Development of Care to the Delivery of Care
Medical Device
Health Insurance
Healthcare Delivery
Healthcare Supply Chain
Del
iver
y of
car
e
![Page 8: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/8.jpg)
04/11/23
Health Care Supply Chain:A Value Based Perspective
“Health sector supply chain refers to the information, supplies, and finances involved with the acquisition and movement of goods and services from the supplier to the end user in order to enhance clinical outcomes while controlling costs.” (Burns 2006)
Developer Producer Purchaser Payer Provider
![Page 9: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/9.jpg)
04/11/23
SupplierManufacturer
(Pharmaceutical,Medical Devices)
Physician/Clinic/Hospital
(Care Provider)
Patient(Consumer)
InsurerFDA
(Food & Drug Administration)
Health Care Supply Chain: Regulation and Reimbursement Perspectives
![Page 10: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/10.jpg)
04/11/23
Diet & Exercise
DrugsDevices
InvasiveProcedures
New BiologicsT
rave
l--T
ou
ris
m
Pay
men
t/R
eim
bu
rsem
ent
Health Care Supply Chain: Care as a Product Bundle of …
![Page 11: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/11.jpg)
04/11/23
“Combine high-tech devices with low-tech care giving, while targeting the mind, body and spirit.”
“Most hospitals are warehouses for sick bodies…Hospitals should be healing environments built for patients.”
Earl Bakken, Inventor of cardiac pacemaker and co-founder of Medtronic Inc.
Source: Pioneer Press, Sept 2, 2006
![Page 12: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/12.jpg)
04/11/23
Medical Device Supply Chain
![Page 13: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/13.jpg)
04/11/23
Medical Device Supply Chain:As Part of the Information-Based Medicine Ecosystem
![Page 14: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/14.jpg)
04/11/23
Medical Device Supply Chain: Key Drivers of Competition
Product innovation Improve clinical outcomes Reduce procedure time and operating costs Enable less invasive procedures Allow patients to reduce or avoid inpatient hospitalizations Shorten recovery time Facilitate patient care in less expensive settings Extend life expectancy
Product performance – product reliability and physician’s perception
Pricing and contracting
Total cost of delivered products (i.e., production efficiencies and supply chain management)
Customer support (Kruger 2005)
![Page 15: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/15.jpg)
04/11/23
Medical Device Supply Chain: Who is the Customer?
Patient (the end customer)
Physician (the care giver)
Health care provider [(hospital system and integrated delivery networks (IDN)]
Purchaser [Group purchasing organization (GPO), wholesaler and distributor]
Sales representative and independent distributor
(Burns and DeGraff 2002)
![Page 16: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/16.jpg)
04/11/23
Medical Device Supply Chain: (Counterintuitive) Principles of Economics (Kruger 2005)
It is assumed implicitly that consumers of goods and services pay for the goods and services – as the price of a good rises, the demand falls.
Medical devices are largely free of this economic law – the demand for medical devices can be exceedingly inelastic (i.e., not depend on price).
Above-average profits are not sustainable, competition from new entrants drive down prices, narrowing margins and reducing profits.
Medical Devices do not appear to be subject to this general rule. Companies (e.g., Johnson & Johnson and Medtronic) have enjoyed sustained above average profits.
Growth in nearly every other industry sector slows as markets become mature and saturated.
In medical devices, growth is sustainable because it is driven by general demographic trends, the continued prevalence of diseases, and the near infinite capacity for absorbing medical technology within the practice of medicine.
![Page 17: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/17.jpg)
04/11/23
Cardiovascular Disease (CVD) Care-CentricMedical Device Supply Chain
![Page 18: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/18.jpg)
04/11/23
(Porter & Olmstead-Teisberg 2006)
Modes of business definition in healthcare are doctor centric, procedure centric, or institution centric, not patient centric.
Patient value in health care delivery….. can only be understood at the level of medical conditions…. Value is determined by how well a provider delivers care in each medical condition, not its overall breadth of services
The Focus on Medical Condition
Cardiovascular Disease (CVD) Care-CentricMedical Device Supply Chain
The relevant business in health care delivery is medical condition seen over full cycle of care.
For example, the business is congestive heart failure, not heart surgery, cardiology, angiography, or anesthesiology.
Business definition always involves a geographic component.
![Page 19: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/19.jpg)
04/11/23
(Source: World Health Organization)
Cardiovascular Disease (CVD) Profile in Men
DALY: Disability adjusted lost year
![Page 20: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/20.jpg)
04/11/23
Cardiovascular Disease (CVD) Profile in Women
DALY: Disability adjusted lost year (Source: World Health Organization)
![Page 21: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/21.jpg)
04/11/23
Cardiovascular Disease (CVD) Treatment Trends in the U.S.
(Source: World Health Organization)
![Page 22: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/22.jpg)
04/11/23
World Health Organization (WHO) Statistics CVD is the commonest chronic illness in both developed and
developing countries, causing the most deaths and the greatest impact on morbidity.
Approximately one-third of the total deaths worldwide are cardiovascular in origin.
The CVD deaths amounted to numbers greater than those compared to the major infectious diseases (AIDS, TB and malaria).
Common perceptions about CVD are: It is a disease of the elderly, a disease of affluence, and even a pleasant way to die.
Cardiovascular Disease (CVD): Perceptions vs. Facts
![Page 23: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/23.jpg)
04/11/23
Cardiovascular Disease (CVD): Perceptions vs. Facts
Major Causes of DeathIn Persons of All AgesIn Low and Middle-IncomeRegions
![Page 24: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/24.jpg)
04/11/23
World Health Organization (WHO) Statistics (contd.)
Contrary to the conventional wisdom, 78% of the CVD deaths occurred not in the high income countries of the world but in the lower and middle income countries.
In sub-Saharan Africa, CVD is a major cause of death in the age range 15-60 years, killing more persons than infectious diseases, and the probability of death from a non-communicable disease is higher that in established market economies.
In India and China, socio-economic changes with individuals moving from a rural community into the cities have resulted in greater prosperity but at the cost of an increase in CVD related disabilities and deaths.
Cardiovascular Disease (CVD): Perceptions vs. Facts
![Page 25: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/25.jpg)
04/11/23
WHO (2003, p. 70) reports “marked disparities in the quality of treatment can be seen in groups of different race, ethnicity, sex, and socioeconomic status. In essence, many patients who could benefit from treatment remain untreated, or inadequately treated,” highlighting the unserved and underserved global demand for CVD care.
WHO’s call for action: “In future, increased emphasis needs to be placed on the appropriate use of proven treatments for everyone with coronary heart disease or stroke.”
Perspectives on Cardiovascular Disease (CVD) Treatment
![Page 26: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/26.jpg)
04/11/23
Diet & Exercise
DrugsDevices
InvasiveProcedures
New Biologics
Tra
vel-
-To
uri
smCardiovascular Disease (CVD) Care
As a Product Bundle of ….
Pay
men
t/R
eim
bu
rsem
ent
PacemakersImplantable DefibrillatorsCoronary StentsProsthetic Valves
Coronary artery bypassBalloon AngioplastyValve Repair & ReplacementHeart Transplant
Cellular Therapy
![Page 27: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/27.jpg)
04/11/23
Cardiovascular Disease (CVD) Care As a Product Bundle of ….
Physician Rankings of the Top 10 Most Beneficial “Medical” Innovations
1. MRI and CT
2. ACE Inhibitors to treat high blood pressure
3. Balloon angioplasty to open blocked blood vessels of the heart
4. Statins to improve lipid metabolism and reduce risk for coronary heart disease and other vascular diseases
5. Mammography
6. Coronary artery bypass graft
7. Proton pump inhibitors and H2 blockers to treat gastro-esophageal reflux disease
8. Selective serotonin reuptake inhibitors and new non-SSRI anti-depressants
9. Cataract extraction and lens implant
10.Hip and knee replacement(Fuchs and Sox 2001)
![Page 28: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/28.jpg)
04/11/23
CVD Care-Centric Medical Device Supply Chain:
Some Considerations
![Page 29: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/29.jpg)
04/11/23
Linking the development and delivery of care for cardiovascular (CVD) diseases: Designing medical device supply chains for the unserved and underserved global economies
Estimating the demand for CVD care emerging from the unserved/undeserved global economies for which medical devices can be an appropriate and effective part of the treatment – assessing the true market potential.
Examining strategies for product design and supply chain design (delivery infrastructure – diagnostic and treatment capability, physical infrastructure) to meet the demands of unserved/underserved global economies
CVD Care-Centric Medical Device Supply Chain:Some Considerations
![Page 30: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/30.jpg)
04/11/23
Low HighAccess/Awareness
Low
High
Affordability
Patient-Centric Design & Delivery of Cardiovascular Disease (CVD) Care
E.g., Sub-Sahara
E.g., Oil RichMiddle-East
E.g., Major MetroCities in India
E.g., Urban U.S.
Policy Contingencies: Regulation – Reimbursement – Recall
CVD Care-Centric Medical Device Supply Chain:Some Considerations
![Page 31: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/31.jpg)
04/11/23
Demandt = f (Affordabilityt, Accesst, Awarenesst)
Awareness • Patient• Physician
• Patient: Cultural and educational• Physician: Education and training
• Diagnostic• Treatment• Follow-up
• Physician & allied health professional capability• Logistical infrastructure• Physical infrastructure: Quality and capacity
Access1
Affordability • Out of pocket• Insurance• Reimbursement
• Financing and leasing• Micro-lending• Remanufactured devices• Low cost product design/re-design
Drivers Typical Types Future Considerations
1“Given either a lack of facilities and operators for percutaneous interventions or long distances to such facilities in many developing countries, we did not evaluate this procedure.”
(Gaziano et al. 2005, p. 651)
CVD Care-Centric Medical Device Supply Chain:Some Considerations
![Page 32: Towards Linking the Development and Delivery of Care for](https://reader035.vdocuments.us/reader035/viewer/2022070313/554b9c91b4c905b3618b4624/html5/thumbnails/32.jpg)
04/11/23
In closing ….
“Healthcare is a peculiar beast where in spite of all the new technology, costs keep going up all the time. That is a strange paradox. We are out to buck that trend. We cannot afford to let the masses be deprived of top class tertiary care.”
(Dr. Devi Prasad Shetty in “Narayan Hrudayalaya Heart Hospital: Cardiac Care for the Poor,” HBS Case April 2006)
Thank you!